Explore

Slice the corpus on any axis.

Filter by firm, year, function, metric or slide category — then see the result as a narrative arc, a treemap of slide types, or a catalog of slides.

clear
51,416 slides across 1229 decks match.
Appendix
Barclays · 2023 · appendix
Appendix
Public Renewable Comparables
Barclays · 2023 · competitive_analysis
Public Renewable Comparables
Specialty Products & Solutions
Barclays · 2023 · other
Specialty Products & Solutions
SPS 2Q Summary
Barclays · 2023 · kpi_dashboard
SPS 2Q Summary
$61.0 — Adjusted EBITDA
Performance Brands
Barclays · 2023 · other
Performance Brands
PB 2Q Summary
Barclays · 2023 · kpi_dashboard
PB 2Q Summary
$85.5 — Sales
Montana/Renewables
Barclays · 2023 · section_divider
Montana/Renewables
M/R 2Q Summary
Barclays · 2023 · kpi_dashboard
M/R 2Q Summary
$12.6 — Adjusted EBITDA
Credit Metrics
Barclays · 2023 · financial_analysis
Credit Metrics
4.0x — Net Debt to LTM Adjusted EBITDA
Capital Structure Overview
Barclays · 2023 · financial_analysis
Capital Structure Overview
4.0x — Net Recourse Debt / LTM Adjusted EBITDA
Accelerated Access Review: UK Mapping
Deloitte · 2015 · cover
Accelerated Access Review: UK Mapping
Dear Reader,
Deloitte · 2015 · disclaimer
Dear Reader,
Contents
Deloitte · 2015 · table_of_contents
Contents
Executive Summary
Deloitte · 2015 · executive_summary
Executive Summary
Challenges to early access
Deloitte · 2015 · problem_statement
Challenges to early access
Four key challenges
Deloitte · 2015 · pain_points
Four key challenges
Challenges: Pharmaceuticals
Deloitte · 2015 · pain_points
Challenges: Pharmaceuticals
Challenges: Medical devices
Deloitte · 2015 · pain_points
Challenges: Medical devices
Challenges: In vitro diagnostics
Deloitte · 2015 · pain_points
Challenges: In vitro diagnostics
Opportunities for improved access
Deloitte · 2015 · framework_other
Opportunities for improved access
Contents
Deloitte · 2015 · table_of_contents
Contents
Accelerated Access Review
Deloitte · 2015 · context
Accelerated Access Review
Workstream 1 objectives
Deloitte · 2015 · section_divider
Workstream 1 objectives
Pharmaceutical pathway summary
Deloitte · 2015 · process_diagram
Pharmaceutical pathway summary
How to read this document (1/2)
Deloitte · 2015 · context
How to read this document (1/2)
How to read this document (2/2)
Deloitte · 2015 · other
How to read this document (2/2)
Contents
Deloitte · 2015 · table_of_contents
Contents
Challenges: Pharmaceuticals
Deloitte · 2015 · pain_points
Challenges: Pharmaceuticals
Pharma: Development
Deloitte · 2015 · section_divider
Pharma: Development
Development: Detailed Pathway
Deloitte · 2015 · process_diagram
Development: Detailed Pathway
Development: Key Challenges
Deloitte · 2015 · pain_points
Development: Key Challenges
Development: Illustrative Quotes
Deloitte · 2015 · quote_slide
Development: Illustrative Quotes
Development: Stakeholder views
Deloitte · 2015 · diagnosis
Development: Stakeholder views
Pharma: Regulation
Deloitte · 2015 · section_divider
Pharma: Regulation
Regulation: Detailed Pathway
Deloitte · 2015 · process_diagram
Regulation: Detailed Pathway
Regulation: Key Challenges
Deloitte · 2015 · pain_points
Regulation: Key Challenges
Regulation: Illustrative Quotes
Deloitte · 2015 · quote_slide
Regulation: Illustrative Quotes
Regulation: Stakeholder Views
Deloitte · 2015 · diagnosis
Regulation: Stakeholder Views
Pharma: National Reimbursement
Deloitte · 2015 · section_divider
Pharma: National Reimbursement
National Reimbursement: Detailed Pathway
Deloitte · 2015 · process_diagram
National Reimbursement: Detailed Pathway
National Reimbursement: Key Challenges
Deloitte · 2015 · pain_points
National Reimbursement: Key Challenges
National Reimbursement: Illustrative Quotes
Deloitte · 2015 · quote_slide
National Reimbursement: Illustrative Quotes
National Reimbursement: Stakeholder Views
Deloitte · 2015 · problem_statement
National Reimbursement: Stakeholder Views
Pharma: Local Commissioning & Adoption
Deloitte · 2015 · section_divider
Pharma: Local Commissioning & Adoption
Local commissioning & adoption: Detailed Pathway
Deloitte · 2015 · process_diagram
Local commissioning & adoption: Detailed Pathway
Key Challenges
Deloitte · 2015 · pain_points
Key Challenges
Local commissioning & adoption: Illustrative Quotes
Deloitte · 2015 · quote_slide
Local commissioning & adoption: Illustrative Quotes
Local commissioning & adoption: Stakeholder Views
Deloitte · 2015 · pain_points
Local commissioning & adoption: Stakeholder Views
Next page →